Oil and Gas Stocks News; In a New Audio Interview at SmallCapVoice.com, Robert McIntosh, President & C.E.O. of American Petro-Hunter, Inc. (OTCBB: AAPH), Provides Details Regarding Recent News

AUSTIN, Texas - June 8, 2011 (Investorideas.com energy newswire) - SmallCapVoice.com, Inc. announced today that a new audio interview featuring, American Petro-Hunter, Inc. (OTC.BB:AAPH) is now available. The interview can be heard http://smallcapvoice.com/blog/6-7-11-audio-interview-with-american-petro-hunter-inc-otcbb-aaph/

SmallCapVoice is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients' financial news releases.
SmallCapVoice also offers individual investors all the tools they need to make informed decisions about the stocks they are interested in. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTC QB, OTC QX and OTC Pink. To learn more about SmallCapVoice and their services, please visit http://www.smallcapvoice.com/services.html.
To sign up for the free small cap stock newsletter, The Small Cap Daily, please visit http://smallcapvoice.com/newsletter.html
About American Petro-Hunter, Inc. (OTCBB: AAPH)
The Company is a goal-oriented exploration and production (E&P) Company aiming to become an intermediate level oil and gas producer within 12 months. The Company is in production at the Poston Project in Trego County Kansas with new drilling activity and production underway at the North Oklahoma Oil Project. With the achievable target of becoming a 1000 BOE producer as our goal, American Petro-Hunter is actively on the "hunt" for domestic petroleum assets. Visit us at: www.americanpetrohunter.com
Contact:
Investor Relations:
Mountainview IR Services, Inc.
1-888-521-7762
investors@americanpetrohunterinc.com
Contact for SmallCapVoice.com:
Stuart T. Smith
512-267-2430
info@smallcapvoice.com

Visit the AAPH showcase profile at Investorideas.com
Request News and Info on AAPH
Disclosure, Disclaimer/ AAPH is a paid advertising client on Investorideas.com.
American Petro-hunter Inc. (AAPH.OB) showcase energy stock on Investorideas.com and energy portals and blogs (averages two thousand per month)

Biotech/Medical Technology Stock News; Aethlon Medical (OTCBB: AEMD) to Discuss Recent Progress at the LHA Life Sciences & Medical Technologies Virtual Conference on June 16

SAN DIEGO � June 8, 2011 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD) the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announces that Chairman and CEO James A. Joyce will provide a company overview, discuss recent developments and review upcoming milestones at the 5th LHA Life Sciences & Medical Technologies Virtual Conference.

The webcast presentation will be available Thursday, June 16, 2011, at 10:00 a.m. Pacific time (1:00 p.m. Eastern time) by visiting the Company's website at: www.aethlonmedical.com
Aethlon further disclosed that Company President Rodney S. Kenley will discuss the role of the Aethlon Hemopurifier® in the treatment of hepatitis C virus (HCV) in a presentation tomorrow at the 20th International Vicenza Course of Hemodialysis and CKD in Vicenza, Italy. The Aethlon Hemopurifier® is first-in-class therapeutic filtration device that selectively removes infectious viruses and immunosuppressive toxins from the entire circulatory system through the use of dialysis machines and other blood circulatory pumps already located in hospitals and clinics worldwide. Mr. Kenley's presentation, "The Treatment of HCV with Affinity Plasmapheresis on Dialysis Machines," will focus on treating HCV in existing dialysis clinics with no change in infrastructure or capital investments. The Hemopurifier® can be used to treat HCV in dialysis patients, in whom the prevalence of HCV is over 100 times higher than the general population, as well as non-dialysis patients. Access to Mr. Kenley's slide presentation will be provided on the Aethlon Medical website after the conclusion of the event.
About Aethlon Medical
The Aethlon Medical mission is to create innovative devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. The Aethlon ADAPT� system is an expansive technology platform that converges affinity drug agents and plasma membrane technology to create therapeutic filtration devices that selectively target the removal of harmful particles from the entire circulatory system. Our lead therapeutic candidate is the Aethlon Hemopurifier®, a device with broad-spectrum capabilities against viral pathogens and immunosuppressive cancer exosomes. In human studies, Hemopurifier® therapy has provided significant viral load reductions in HIV and hepatitis C virus infected individuals without the administration of antiviral drugs. We are now focused on advancing our Hemopurifier® as an adjunct strategy to improve the benefit of established infectious disease and cancer treatment regimens. Based on studies conducted by government and non-government research organizations, the Hemopurifier® is also a leading broad-spectrum treatment candidate to address bioterror and pandemic threats. For more information, please visit www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT� system, the Aethlon ADAPT� systems' ability to selectively remove disease-related particles from the entire circulatory system without the loss of essential blood components or its ability to eliminate the need to infuse drug agents into the body, the Company's ability to commercialize its Hemopurifier® in India, the capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
Jody Cain
Senior Vice President, Lippert/Heilshorn & Associates
310.691.7100
jcain@lhai.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307
jps@aethlonmedical.com

AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock)
Effective March 15, 2011

Gold Stocks; GOLD BULLION (TSX-V: GBB) IDENTIFIES STRONG, NEW VEIN STRUCTURE AT CASTLE SILVER MINE, GOWGANDA

VANCOUVER - June 8, 2011 (Investorideas.com Mining stocks Newswire) - Gold Bullion Development Corp. (CDNX:GBB.V) (Other OTC:GBBFF.PK) ("Gold Bullion") announces that it has completed a 43-101 Technical Report on its Castle Silver Mine property, which has been filed on SEDAR and can also be viewed on the Company's website at http://www.GoldBullionDevelopmentCorp.com. Gold Bullion is nearing completion of its 6000m first-phase drill program with a total of 4861 metres, as of May 31st, having been completed in 10 holes. A strong new vein structure was identified at the location of the first IP target tested.

The Company's Castle Silver Mine property, located 85 kilometres northwest of the historic silver camp in Cobalt, Ontario consists of 34 leased mining claims and two licenses of occupation located in Haultain and Nicol Townships, covering approximately 564.4 hectares. The mine has been in operation at various times from 1917 to 1989 and produced a total of 763,127,010 grams of silver from the No. 3 shaft. This included Agnico-Eagle Mines Ltd.'s production from 1979 to 1989 which came to 101,024 tonnes milled; 91,421,294 grams silver; 34,597 kilograms cobalt and 10,180 kilograms copper. Operations shut down in 1989 due to low silver prices.
Mine workings were originally accessed by an adit level entrance on the 21.3 metre (70-foot) level as well as a vertical shaft. Water level measurements have ascertained that this uppermost level is above the mine's water level. Based on this determination, the Company has submitted a preliminary closure plan to allow the re-opening of the adit to map and re-sample this upper level. This can be done without having to dewater the mine. Once this initial re-evaluation has been completed, the Company will determine whether to proceed with the complete dewatering of the workings.
The mandate of this first phase of drilling is to identify the geometry and stratigraphy of the mafic diabase intrusive sill to which the silver-cobalt quartz-carbonate veins are spatially related. Of particular importance are fault structures sub-parallel to the contacts of this intrusive body. The drilling is attempting, at the same time, to define the strength of known vein structures from historic workings as well as testing specific IP targets identified by a recent geophysical survey.
To date, several significant vein structures have been intersected. The potential extensions to two strong historical structures have been tested but need further work before they can be confirmed. No sample analyses have been received to date. In keeping with the aim of mapping the stratigraphy of the 300m-thick intrusive sill, four holes have traversed the entire thickness enabling a detailed analysis of subtle differences in mineralogy and alteration and the identification of the location the low-angle faults which are important mineralization indicators.
Historically, exploration in the Gowganda - Elk Lake area has focused on the upper one-third of the Nipissing diabase sill and most of the resulting historic production from the Gowganda area has been mined from this horizon. However, an estimated 75 percent or more of the silver mined from all the silver mines between Gowganda and Silver Centre in South Lorrain south of Cobalt, Ontario - has been mined from outside this horizon.
About Gold Bullion Development Corp.
Gold Bullion Development Corp. is a TSX Venture listed junior natural resource company focusing on the exploration and development of its Granada Gold Property near Rouyn-Noranda, Quebec, and its high grade Castle Silver Mine in Gowganda, Ontario.
For more information on Gold Bullion Development Corp. (TSX-V: GBB, OTC PK: GBBFF), visit our web site: http://www.GoldBullionDevelopmentCorp.com
Qualified Person
Mr. Doug Robinson, P.Eng., is the qualified person as defined by National Instrument 43-101 who supervised the preparation and verification of the technical information in this release.
"Frank J. Basa"
Frank J. Basa, P.Eng.
President and Chief Executive Officer
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming work programs, geological interpretations, receipt of property titles, potential mineral recovery processes, etc. Forward-looking statements address future events and conditions and therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

Visit the GBB showcase profile at Investorideas.com
Request News and Info on GBB
Disclosure, Disclaimer/ GBB is a paid advertising client on Investorideas.com and our mining portals.

Q&A Interview with President/CEO of Gold Stock Soltera Mining Corp. (OTCPK: SLTA): Ethical Gold in Argentina

Point Roberts, WA - June 08, 2011 - www.InvestorIdeas.com, a leader in sector stock research including mining stocks, release a Q&A interview with Dr. Fabio Montanari, President/CEO of Soltera Mining Corp. (OTCPK:SLTA) (FRANKFURT:SN7) for interested gold stock investors.

On May 5th, 2011 Soltera reported some exciting gold assay results from a chip and channel program on sections of the 14 km long gold-bearing quartz vein system that spans their El Torno property in northern Argentina. Those results included a mind-boggling 1.5 meters at 376 g/t. This announcement, however, came on the heels of an April 27th release stating that test work on an eluvial (weathered surface material) area designated to provide feed for the existing gravity plant showed insufficient gold for exploitation.
Then on May 25th Soltera announced that Goldlake Italia S.p.A ("Goldlake"), a company that has an agreement to supply "ethical gold" to Cartier Jewelers, intends to invest a further US$900,000 into Soltera by June 30th 2011.
InvestorIdeas.com interview with Dr. Fabio Montanari sheds light on the relevance of these three announcements and tells investors about his current plans at Soltera Mining's flagship Argentine gold property, El Torno.
Dr. Fabio Montanari has an international mining career of over twenty-five years, including senior experience spearheading advanced exploration and mining activities in Africa, South America, Europe, Canada and the United States for a host of internationally recognized exploration and mining companies including: Asarco (US), Golden Star (UK), ENI Group (Italy) and Normabec (CAN). Dr. Montanari has also been a geological consultant to the United Nations under the U.N. Technology Cooperation Schemes.
Q- Investorideas.com
Dr. Fabio Montanari, let's start with the two announcements regarding assay results. They seem contradictory, with one reporting low gold values and the other some very high gold values, so what does this mean?
A- Fabio Montanari
The difference is because the samples were from test work on two very different types of gold deposit.
The main potential of the El Torno property is for large deposits of vein and bedrock gold, but there are also much smaller deposits of weathered surface (called eluvial) material that can contain free gold. The first announcement concerned test work on eluvial material whereas the second concerned analyses from part of the main vein system.
Q- Investorideas.com
Why bother with the eluvial deposits if they are small and, in any case what went wrong with the eluvial test work?
A- Fabio Montanari
We were looking at the eluvial material because there is a simple gravitational processing plant already in place that had been used successfully in the past by the mineral title owner and it offered the real possibility of generating a rapid cash flow that would pay for exploration of the main targets. Initial operation of the plant produced gold in the form of tiny nuggets and the next logical step was to test an area of potential eluvial feedstock to see if there was enough for a commercial operation. Any production by this means would be ideal for Goldlake's agreement to supply ‘ethical gold' to Cartier.
The sampled area, about 35 of the 7 861hectares (19,424 acres) included in the property, was selected because it had a good thickness of weathered material, all the necessary permissions for surface extraction, and is relatively close to the processing plant. Part of the area had also been worked previously by the mineral title owner. However, extensive and detailed test work showed that although small amounts of gold are distributed widely throughout the area, the tonnage of material containing higher values is insufficient to justify a commercial operation from this location. There was simply less gold than we had anticipated and, as a result, we cannot go into production immediately as we wished. There are, however, other areas of eluvial material throughout the property that could contain gold and these will be examined in due course.
Q- Investorideas.com
So what is the significance of the very high gold values in the second announcement?
A-Fabio Montanari
The high gold values are very exciting and very significant.
We already knew from old records that a gold-rich zone, said to be about one and a half meters wide, extends along the western edge of the main vein system. Drilling in the 1990s showed that the zone extends to at least 110 meters depth and suggested an average gold grade around 10 gpt. Soltera geochemical surveys also suggest that the zone extends for most of the 14 km vein length. This gold zone is a major exploration target.
Although we had been concentrating on eluvial material, I decided to look more closely at surface expressions of the gold zone. I selected a 300 meter long stretch marked by old workings and trenches, and took samples of various rock types such as white quartz or iron-rich breccias to find out where gold was concentrated. A few were simply grab samples (lumps of a particular rock type), but most were channel samples which means literally cutting a channel several centimeters wide and deep through the rock over a distance of 1 or 1.5 meters. The gold analysis of a channel sample indicates the average gold over the length sampled.
The results were startling to say the least. They included channel samples of 6.5 meters with between 6.2 and 8.8 g/t Au, 1 meter at 14.95 g/t Au, 1 meter at 20.9 g/t Au, and 1.5 meters at 376 g/t Au. The mean value of the 17 samples containing more than 1 g/t Au (with the 376 g/t Au cut to 100 g/t Au) was 11 g/t Au.
The data confirms the existence of the rich gold zone along the flank of the main vein as indicated by earlier drilling and indicates that in some places it is considerably thicker than previously thought (up to 6.5 meters). Some gold mineralization was even detected in part of the main vein system where it had not been previously recognized. The results open up all sorts of possibilities for the future, including that of possible surface production from ‘hot spots' over parts of the vein. It definitely means there should be intensive sampling along the full 14 km length of the vein system.
Q- Investorideas.com
And what about the Goldlake announcement?
A-Fabio Montanari
Goldlake evidently appreciate the potential for gold at El Torno and decided to back us despite the setback over eluvium gold production. We are really looking forward to moving rapidly on some serious exploration of the main vein and dispersed bedrock gold targets.
Q- Investorideas.com
So what's next for Soltera?
A- Fabio Montanari
Intensive exploration of the major gold targets and fulfilling the listing requirements.
Under the terms of the agreement with the mineral title owner, we have eighteen months to decide whether or not the property is worth purchasing outright. This means we have to acquire sufficient information to make a firm decision.
The next step will be detailed mapping and sampling along the full length of the vein and over parts of the dispersed gold targets that are marked by strong geochemical anomalies. At the same time, we are planning a geophysical survey over part of the main vein system. The net result of this work will be to define drill targets and we intend to start drilling during the next field season which commences in September this year. If ‘hot spots' are detected along the gold-rich zone, we will look at the possibility of future surface production, but our main emphasis must be on the major targets.
In addition, we intend to bring all our SEC and BCSC filings up to date in order to become fully compliant with all reporting procedures.
About El Torno
The El Torno project is located in the extreme north of Argentina in rolling country of the high Andes at a height of around 4,000 meters. Soltera holds options over 78 km 2 of highly prospective ground that contains a very large gold-bearing quartz vein system extending intermittently for 14 km with veins up to 20 meters wide, and the area has potential for major gold deposits of two types; large gold-rich quartz vein deposits suitable for underground mining, and gold-bearing quartz vein swarms within the country rocks suitable for large-scale open-pit mining.
Investors can view the mining company profile for Soltera Mining Corp. at http://www.investorideas.com/CO/SLTA/
Soltera Mining Corp. (OTCPK: SLTA) is a gold exploration company concentrating on its large-scale El Torno Gold Project in the Province of Jujuy in north-west Argentina. Soltera is an unusual exploration company in the sense that it is following two distinct lines of action: the first is to explore potentially large vein and dispersed gold deposits that occur within the 78 km2 title area; while the second is to develop the easily exploited and substantial surficial gold deposits that have formed by weathering of the underlying gold-bearing bed rocks.
Visit the company website athttp://www.solteramining.com/
Request news and stock alerts from Soltera Mining Corp. http://www.investorideas.com/Resources/Newsletter.asp
Contacts:
Soltera Mining Corp.
Fabio MontanariPresident/CEO
1-888-768-5552 or 1-303-800-5752
info@solteramining.com
fmontanari@solteramining.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Sign up for the free investor stock alerts in leading sectors! http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer: The following company profile release for Soltera Mining is a paid for submission as a showcase companies (five hundred per month) Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions, company profile submissions and online advertising.
Disclaimer/Disclosure: http://www.investorideas.com/About/Disclaimer.asp
http://www.investorideas.com/About/News/Clientspecifics.asp
For Additional Information about Investorideas.com mining portals and becoming a showcase stock:
800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
Disclosure: SLTA is a paid advertising client on Investorideas.com and our mining portals.

Oil and Gas Stock Q&A Interview with Kim Bradford, President and CEO of Osage (OTCBB: OEDV)

Point Roberts, WA - June 7 , 2011 (Investorideas.com Energy Newswire) - www.InvestorIdeas.com, a leader in sector research including energy stocks, features a recent interview with Kim Bradford, President and CEO of Osage Exploration and Development, Inc. (OTCBB: OEDV), following their news of the joint venture with Slawson Exploration Company, Inc. and U.S. Energy Development Corporation. Mr. Bradford discusses Osage's partners, reserves and potential for the Nemaha Ridge Project in Oklahoma.

Interview Excerpt:
Q: Investorideas.com
The Company just announced it closed an agreement whereby Slawson Exploration Company, Inc. and U.S. Energy Development Corporation have acquired 45% and 30% respectively of Osage's Nemaha Ridge project in Oklahoma for gross consideration of $4,875,000.00 plus a 10% net carry on the first three horizontal Mississippian wells. Can you discuss the significance of the partners and what role they play moving forward?
A: Kim Bradford, President and CEO of Osage Exploration and Development, Inc.
Yes I can. Large oil companies have departments full of people and those people tend to be interchangeable in any given situation. Because we are not a large oil company, the individuality of the partners becomes paramount in determining how we go forward. In our situation, the Principals of each company come together and make decisions. The fact that Slawson and USEDC have done many deals together over the years, and the fact that Osage's VP Exploration, Greg Franklin, has known Steve Slawson for over 20 years means that from day one this partnership has a culture of trust and long term respect for each other. This is essential for success because in creating this financial partnership we have also created the Operating team. In this project there are no passive partners, we all bring a level of expertise in the various functional areas necessary to drill and exploit this resource. We are all rallying behind our Operator, Slawson, to provide leadership, but Slawson has selectively asked each of us to perform certain tasks along the way. From Osage's perspective, we have gained a tremendous amount of engineering expertise that we simply did not have. We have gained access to two superbly experienced land teams to complement the work that we have done already. Perhaps most importantly, Slawson as a driller owns rigs that we may elect to use in our project. The value of that can not be understated because as the Horizontal Miss play continues to heat up, it is pretty easy to forecast equipment shortages, and we have the solution already in place. This is a superb team with an abundance of talent, expertise, equipment and experience in horizontal drilling.
Full interview: http://www.investorideas.com/CO/OEDV/news/2011/05312.asp
Recent news:
Osage (OTCBB: OEDV) Announces Joint Venture with Slawson Exploration Company and U.S. Energy Development Corporation for Horizontal Mississippian Nemaha Ridge Project
SAN DIEGO - May 27, 2011 (Investorideas.com energy stocks newswire) - Oil and Gas News - Osage Exploration and Development, Inc. (OTCBB: OEDV) reports it has closed an agreement whereby Slawson Exploration Company, Inc. and U.S. Energy Development Corporation have acquired 45% and 30% respectively of Osage's Nemaha Ridge project in Oklahoma for gross consideration of $4,875,000.00 plus a 10% net carry on the first three horizontal Mississippian wells. Full news: http://www.investorideas.com/CO/OEDV/news/2011/05272.asp
About Osage Exploration and Development, Inc.
Based in San Diego, California with production offices in Oklahoma City, Oklahoma, and executive offices in Bogotá, Colombia, Osage Exploration and Development, Inc. is an independent exploration and production company with interests in oil and gas wells and prospects in the US and Colombia. www.osageexploration.com
Follow (OTCBB: OEDV) on Twitter.com
http://twitter.com/#!/OsageOEDV
About Slawson Exploration Company, Inc.
Headquartered in Wichita, KS, with regional offices in Denver, Houston, and Oklahoma City, Slawson was founded in 1957. http://www.slawsoncompanies.com/exploration.html
About U.S. Energy Development Corporation
U.S. Energy Development Corporation was formed in 1980 as a successor to Oilmark & Company, Inc., founded in 1978. The company has consistently been ranked among the Top 50 Independent Oil & Natural Gas Drillers in the United States and is one of the largest drillers in both New York and Pennsylvania. Since 1980, U.S. Energy has acted as operator with respect to the drilling of more than 2,500 wells. www.usenergydevcorp.com
Safe Harbor Statement
The information in this release includes certain forward-looking statements as defined by the Securities and Exchange Commission that are based on assumptions that in the future may prove not to have been accurate. Those statements and Osage Exploration and Development, Inc. are subject to a number of risks, including production variances from expectations, volatility of product prices, inability to raise sufficient capital to fund its operations, environmental risks, competition, government regulation, and the ability of the Company to execute its business strategy, among others.
Contact:
Osage Exploration and Development, Inc.
Kim Bradford, President and CEO
Phone: 619-677-3956
Fax: 619-677-3964
kbradford@osageexploration.com
www.osageexploration.com
Osage Exploration and Development, Inc. (OEDV.OB) is a showcase oil and gas stock on Investorideas.com
Visit the company showcase profile at Investorideas.com
http://www.investorideas.com/CO/OEDV/
Request news and trading alerts on OEDV
http://www.investorideas.com/Resources/Newsletter.asp
Research more oil and gas stocks with the oil and gas stock directory at Investorideas.com - lists over 600 stocks including Bakken stocks
http://www.investorideas.com/OGSN/Stock_List.asp
Disclaimer: Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Disclosure: OEDV is a paid advertising oil and gas company on Investorideas.com - Disclosure: (6 months starting May 24, 2011 thirty five hundred per month, 100,000 144 shares)
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp  
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp  
C Van Zant: 800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com

Osage Exploration and Development, Inc. (OEDV.OB) is a showcase oil and gas stock on Investorideas.com
Visit the company showcase profile at Investorideas.com
Request news and stock alerts for Osage Exploration and Development, Inc. (OEDV.OB)
Disclosure: (6 months starting May 24, 2011 thirty five hundred per month, 100,000 144 shares)

Biotech Q&A; BioSante Announces Completion of Enrollment in LibiGel Safety Study

Point Roberts, WA, LINCOLNSHIRE, Ill - June 7, 2011 - (Investorideas.com newswire.com) Investorideas.com, an investor research portal covering leading sectors including biotech and pharma stocks, features an exclusive Q&A interview and update with Mr. Stephen M. Simes, president and chief executive officer of BioSante Pharmaceuticals. Mr. Simes discusses the significance of the Company’s completion of enrollment in its ongoing LibiGel (testosterone gel) Phase III cardiovascular and breast cancer safety study.

LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who suffer from female sexual dysfunction (FSD).
BioSante Pharmaceuticals Interview
Q: Investorideas.com
Stephen, the company has announced completion of the enrollment in its ongoing LibiGel (testosterone gel) Phase III cardiovascular and breast cancer safety study. Can you explain to investors how it was determined that the current enrollment is sufficient?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
Yes, based on the last unblinded statistical analysis by the independent statistician of the Data Monitoring Committee, it was determined that according to the FDA-agreed sample size analysis enrollment should stop, based on meeting a minimum 90 percent predictive probability of success of the safety study to show the safety of LibiGel at the primary data analysis. As per the protocol, the safety study will continue for 12 months of therapy from the last subject enrolled before the primary analysis will be conducted by BioSante, which will provide the data for BioSante's new drug application (NDA) submission anticipated to be made in 2012. The study will continue for five years.
Q: Investorideas.com
How does this impact the timeline for a new drug application (NDA) submission?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
Our projected timeline is to submit an NDA to the FDA seeking approval to market LibiGel by the end of 2012.
Q: Investorideas.com
Can you explain to investors the timelines and the next stages of the Phase III LibiGel safety study?
Based on the LibiGel safety study protocol, the primary analysis of data will be conducted in 12 months. This will put us in a position to submit the NDA by the end of 2012.
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
Q: Investorideas.com
LibiGel is currently the only product in the world in Phase III clinical development for the treatment of HSDD- Can you explain to new investors the significance of being first to market?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
We believe the potential market for products to treat women's sexual health is well over $1 billion in the U.S. alone. We also believe that LibiGel will be the first product approved for the treatment of menopausal women in this indication. Being first to market will result in gaining the majority of the available market.
Related News Release:
Pharma News; BioSante Pharmaceuticals (NASDAQ: BPAX) Completes Enrollment in LibiGel® Phase III Safety Study
May 31, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX), today announced completion of enrollment in its ongoing LibiGel (testosterone gel) Phase III cardiovascular and breast cancer safety study. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is no FDA-approved product.
BioSante has been informed by the LibiGel safety study independent Executive Committee regarding the outcome of the sample size analysis that determines the number of subjects to be enrolled in the LibiGel Phase III safety study. The FDA-agreed sample size analysis indicates that enrollment should stop, based on meeting a minimum 90 percent predictive probability of success of the safety study to show the safety of LibiGel at the primary data analysis. As per the protocol, the safety study will continue for 12 months of therapy from the last subject enrolled before the primary analysis will be conducted by BioSante, which will provide the data for BioSante's new drug application (NDA) submission anticipated to be made in 2012. The study will continue for five years.
Full News at: http://www.investorideas.com/CO/BPAX/news/2011/05311.asp
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel ® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA). BioSante's first FDA-approved product is Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other BioSante products are Bio-T-Gel™, a testosterone gel for male hypogonadism, for which an NDA is pending, licensed to Teva Pharmaceuticals, and an oral contraceptive in Phase II clinical development using BioSante patented technology. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as “will,” “continue,” “could,” “believe,” “intends,” “continue,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning, derivations of such words or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly report on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
For more information, please contact:
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953; tswanson@troutgroup.com azachary@mckinneychicago.com
For Media:
McKinney/Chicago
Alan Zachary
312-506-5220; azachary@mckinneychicago.com
BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX) is a featured showcase biotech/pharma stock on Investorideas.com
The full BPAX company profile is available at http://www.investorideas.com/CO/BPAX/ for interested biotech investors.
Request news, updates and trading alerts on BPAX and other showcase stocks http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory:
http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including biotech and pharma stocks.
Disclaimer: The following news/content is paid for as part of the BPAX showcase program (two thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp 
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp 
Source: Investorideas.com, BioSante, Investorideas.com
Contact Investorideas.com
800 665 0411 cvanzant@investorideas.com

This summary is not available. Please click here to view the post.

Biotech/Pharma Stocks News; UV Flu Technologies (OTCBB: UVFT) Receives First Order for the Chinese Marketplace

CENTERVILLE, MA – June 7, 2011 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") announced today that it had received its first order of ViraTech UV-400's for test and evaluation for the Chinese marketplace. The units will be manufactured to Chinese electrical standards, and will be shipped for evaluation to 3 hospitals in different Chinese cities.

"This is our first entry into the biggest potential market for our products in the world," said John Lennon, President of UV Flu. "China has approximately 330,000 hospitals, with even greater numbers of clinics, and the spread of airborne bacteria and viruses is epidemic in many areas. Children in many cities are examined before they're allowed on school grounds, and it's not uncommon to see large numbers of people in hospital waiting areas with IVs, providing a fertile environment for the airborne spread of bacteria.
"We have been patiently building our brand over the last several months, and the results are about to be realized. We now have RX-3000s in a significant number of the top hospitals in America, and are currently back-ordered, while a new program we are starting with Hotels later this month is expected to put us in a similar back-order situation on the UV Flu side. We also hope to have our new initiatives in China, along with the Mideast, introduced later this month," said Mr. Lennon.
Further details regarding the Company's business, acquisitions, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information, visit: www.uvflutech.com.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com

SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/

Biotech and Pharma News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) To Present at Jefferies Global Healthcare Conference


LINCOLNSHIRE, Ill. - June 7, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) today announced that Phillip B. Donenberg, BioSante’s senior vice president of finance and CFO, will speak on Thursday, June 9, 2011 at 4:00pm eastern time at the Jefferies 2011 Global Healthcare Conference at the Grand Hyatt Hotel in New York City.

Mr. Donenberg will provide an overview of BioSante, as well as an update on the LibiGel® (testosterone gel) Phase III clinical development program.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as “will,” “continue,” “could,” “believe,” “intends,” “continue,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning, derivations of such words or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly report on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com

Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com (1000 per month).

Oil and Gas Stocks News; American Petro-Hunter's (OTCBB: AAPH) North Oklahoma NOS122 Oil Well in Production

SCOTTSDALE, AZ � June 6, 2011 (Investorideas.com energy newswire) - American Petro-Hunter, Inc. (OTC.BB:AAPH) ("American Petro-Hunter" or the "Company") is very pleased to report that the recently completed NOS122 well is undergoing production testing and appears to be a strong producer and is outperforming expectations to date.

The NOS122 well is located at the Company's North Oklahoma Project. The production test and evaluation phase has been ongoing over the past few weeks with high gravity light oil produced to the storage tank from a 6 foot pay zone. The oil cut has been steadily over 90% with some associated gas. The well has been producing oil at rates in a broad range generally between 50 and 70 barrels per day.
Although a stable daily production rate hasn't yet been established, the Company has been informed by the operator that the pay zone would benefit from a light fracture stimulation which would in all likelihood allow a significant increase in daily rates. The partners are now preparing a simple frack plan that will be implemented in the upcoming days.
The establishment of a full tank battery and ancillary production facilities is in the final stages of construction on the lease. Currently, oil in the onsite storage tank is being prepared for sale to the local purchaser and inaugural sales are expected shortly. As reported earlier, the partners have identified a minimum of 3 additional offsets to the NOS122 for future development.
Company President Robert McIntosh states, "We are very pleased at the early test results at NOS122 and to be producing oil at levels that have exceeded our expectations. The plan to stimulate the reservoir and bring on even more oil, as well as our intent to drill additional wells very shortly, is rapidly moving this leasehold into becoming a key component of our growing production portfolio."
American Petro-Hunter has a 50% working interest in the NOS122 and oil is sold to Sunoco, the regional purchaser.
About American Petro-Hunter, Inc. (OTCBB: AAPH)
The Company is a goal-oriented exploration and production (E&P) Company aiming to become an intermediate level oil and gas producer within 12 months. The Company is in production at the Poston Project in Trego County Kansas with new drilling activity and production underway at the North Oklahoma Oil Project. With the achievable target of becoming a 1000 BOE producer as our goal, American Petro-Hunter is actively on the "hunt" for domestic petroleum assets. Visit us at: www.americanpetrohunter.com
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of our exploration program at our properties and any anticipated future production. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with petroleum exploration and development stage exploration companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-KSB for the most recent fiscal year, our quarterly reports on Form 10-QSB and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
American Petro-Hunter, Inc.
Robert McIntosh
President & C.E.O.
To find out more about American Petro-Hunter, Inc. (OTC.BB:AAPH), visit our website at www.americanpetrohunter.com
Contact:
Investor Relations:
Mountainview IR Services, Inc.
1-888-521-7762
investors@americanpetrohunterinc.com

Visit the AAPH showcase profile at Investorideas.com
Request News and Info on AAPH
Disclosure, Disclaimer/ AAPH is a paid advertising client on Investorideas.com.
American Petro-hunter Inc. (AAPH.OB) showcase energy stock on Investorideas.com and energy portals and blogs (averages two thousand per month)

Biotech/Pharma Stocks News; UV Flu Technologies (OTCBB: UVFT) Introduces "RX Air Plus," One of the World's Most Advanced Air Purification Systems

CENTERVILLE, MA � June 6, 2011 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce it has commenced marketing the "RX Air Plus" Air Purification System, which the Company believes could revolutionize the air purification marketplace.

The new system may prove to be the most effective air purification system in the world today, as the "RX Air Plus" System packages the RX-3000, built by the Company's RxAir subsidiary, along with 2 ViraTech UV-400 units. The Company believes this to be the only air purification system in the world utilizing two different FDA cleared Class II Medical devices as an integrated system. RX Air Plus brings together the two technologies, which combine to kill over 99% of bacteria and other contaminants, while reducing all odors and volatile organic compounds, as well as capturing over 99.97 % of all particulates within indoor areas up to 1500 square feet in size.
"No other Company offers a system which matches the capabilities of these combined technologies," said John Lennon, President of UV Flu Technologies. "The 'RX Air Plus' offers two of the most unique and effective products in the air purification marketplace today. The two ViraTech UV-400 units utilize hi-intensity germicidal UV lamps contained within a patented cartridge, which kills organic contaminants while also breaking down odors and concentrations of VOCs. The RX-3000 is one of the finest HEPA based air purifiers, capturing over 99.97% of particulates. The quality of indoor air protected by this system is typically purer than outdoor air while never having to open a window. The Company is offering the system to new customers and distributors immediately. We also plan to approach the over 1000 customer locations already utilizing the RX-3000 as possible upgrade opportunities."
"We also believe this system is going to have numerous applications in the Mideast, where microscopic sand particles are a major issue with respect to poor indoor air quality. To this end, the Company is in talks with several companies with respect to distribution in the Mideast, and expects to have an agreement in place this quarter," said Mr. Lennon.
Further details regarding the Company's business, acquisitions, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information, visit: www.uvflutech.com.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com

SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/
Request info:
http://www.investorideas.com/Resources/Newsletter.asp

Oil and Gas Investor Alert; Osage (OTCBB: OEDV) Mississippian Formation Recoverable Reserves Data Highlights

Point Roberts, WA - June 6, 2011 (Investorideas.com Energy Newswire) - Investorideas.com, a leader in sector research including oil and gas stocks, issues a trading alert, stock chart and recoverable reserves data highlights for Osage Exploration and Development, Inc. (OTCBB: OEDV). The recoverable reserves data was prepared by Pinnacle Energy Services, LLC of Oklahoma City.

Since 2007, several operators have been drilling horizontally and completing the Mississippi formation. Based on available public information, SandRidge Energy and Chesapeake Energy have completed over 45 horizontal wells in Woods and Alfalfa Counties, with initial rates ranging up to 1250 BOPD and 3100 Mcfd. Although a distance away, the Osage prospects are approximately on strike with the Woods and Alfalfa County wells.
Excerpts highlighting recoverable reserves on the Osage acreage :
The prospects are located in Townships T16-19N, 3&4W of Logan County, Oklahoma. Pinnacle relied on geological maps, log data, and drilling and completion information provided by Osage which was supplemented by well data, production data, and other information gathered from public sources.
In summary, based on volumetric calculations, the calculated projected oil and gas recoverable volumes per 640 acre section are:
Marshall Ridge 1,043,000 bbls oil and 3,128 Mmcf natural gas
Crescent Ridge 909,000 bbls oil and 3,634 Mmcf natural gas
Cimarron Ridge 824,000 bbls oil and 4,118 Mmcf natural gas
The overall arithmetic average of the three prospects is 992,000 bbls of oil and 3.5 BCF of natural gas per section.
Osage Exploration and Development, Inc. currently owns in excess of 14 net sections, broken down thusly:
Marshall Ridge approximately 10 sections
Crescent Ridge approximately 3 sections
Cimarron Ridge approximately 1 section
The full, unabridged report done by Pinnacle Energy Services, LLC is available on the Osage Exploration website, www.osageexploration.com
Full news http://www.investorideas.com/CO/OEDV/news/2011/05021.asp
Visit the company showcase profile at Investorideas.com
http://www.investorideas.com/CO/OEDV/
Company News:
Osage (OTCBB: OEDV) Joint Ventures Its 10,000 Acre Horizontal Mississippian Nemaha Ridge Project
Full News: http://www.investorideas.com/CO/OEDV/news/2011/05261.asp
About Osage Exploration and Development, Inc. ( OTCBB: OEDV)
Based in San Diego, California with production offices in Oklahoma City, Oklahoma, and executive offices in Bogotá, Colombia, Osage Exploration and Development, Inc. is an independent exploration and production company with interests in oil and gas wells and prospects in the US and Colombia. www.osageexploration.com
Follow (OTCBB: OEDV) on Twitter.com
http://twitter.com/#!/OsageOEDV
Request news and trading alerts on OEDV
http://www.investorideas.com/Resources/Newsletter.asp
Research more oil and gas stocks with the oil and gas stock directory at Investorideas.com – lists over 600 stocks including Bakken stocks
http://www.investorideas.com/OGSN/Stock_List.asp
Disclaimer: Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Disclosure: OEDV is a paid advertising oil and gas company on Investorideas.com - Disclosure: (6 months starting May 24, 2011 thirty five hundred per month, 100,000 144 shares)
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp  
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp  
C Van Zant: 800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com

Osage Exploration and Development, Inc. (OEDV.OB) is a showcase oil and gas stock on Investorideas.com
Visit the company showcase profile at Investorideas.com
Request news and stock alerts for Osage Exploration and Development, Inc. (OEDV.OB)
Disclosure: (6 months starting May 24, 2011 thirty five hundred per month, 100,000 144 shares)

Cloud Computing Stock News; Gar Wood Securities Initiates Coverage on GBS Enterprises (OTCBB:GBSX) With $9 Price Target

NEW YORK - June 6, 2011 (Investorideas.com cloud computing stocks newswire) � GBS Enterprises (OTCBB:GBSX), announced today that Gar Wood Securities, a full service institutional broker--dealer located in Chicago, Il, has initiated coverage and issued its Insight Equity Research Report on the Company with a Buy rating and $9 per share target price.

Gar Wood recently raised $7.55MM for GBS with warrant coverage that will result in an additional $9MM funding to the Company.
Some excerpts from the Gar Wood research report are as follows:
Key Points

• As the largest provider of products and services to IBM's Lotus market, GBS has a long history of working with IBM. The Company is currently working with IBM to market its GROUP Live Cloud Platform and Notes Transformer.
• The Cloud Computing market was estimated to be $16.5 billion in 2009 and is predicted to increase to $55.5 billion in 2014. GBS competes in this market through its Cloud Automation Platform, which can be customized for a wide range of customers, and its software solutions which are now available in a SaaS format.
• Due to cost savings and efficiencies, it is estimated that 40% of all business applications will be delivered via the cloud by 2014. We believe GBS' Transformer software provides the only timely, cost effective method to move Lotus Notes applications to the Cloud, without having to rewrite entire applications or move away from Notes.
• We estimate the total market potential for the Transformer to be roughly $18.0 billion, of which we believe GBS's realizable market could be roughly $5.5 billion. The bulk of this potential revenue would have little cost associated, as it incurs little cost on IBM sales and primarily just programmer cost on applications it transforms.
• The Company's Transformer was awarded the CTO Award at Lotusphere in 2011, while its Cloud Platform won the IBM Bestseller Award at Lotusphere in 2011 after winning the CTO Award at the 2010 Lotusphere.
• Management has a track record of completing M&A deals that add new customers and/or technologies at low valuations. It is also working to expand its distribution channels, similar to its recent agreement with Alliance Technology Group to market to the government sector.

Caution Concerning Forward-Looking Statements
This release contains statements, which may constitute "forward-looking statements" under the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or expectations of the Company. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that results may differ materially from such statements.
About GBS Enterprises, Inc.
GBS Enterprises (OTCBB:GBSX), is the parent company of Group Business Software which provides product and services for the IBM Lotus market. The company boasts more than 4,000 customers worldwide with more than 4 million users of their products and services. GBS has offices in New York, Boston, Atlanta, Toronto, London, Manchester, Copenhagen, and throughout Germany. Its European headquarters is in Frankfurt, Germany and North American headquarters is located in New York City. For more information please visit www.gbs.com.
Contact:
GROUP Business Software:
Marketing and Communications Contact: Michael Baum
Corporate Communications, michael.baum@us.gbs.com
GBS Enterprises:
Investor Relations Contact:
Gary MacDonald, EVP and Chief Business Development Officer
gmacdonald@gbsx.us Tel: 917-477-9509

Visit the GBSX company profile on Investorideas.com
Request news and info on GBSX

Disclosure: GBS Enterprises, Inc. (OTCBB:GBSX) is a paid showcase tech stock, cloud computing stock on Investorideas.com (April 2011 - 1500 per month by third party)
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp